NTCP model for hypothyroidism after supraclavicular-directed radiation therapy for breast cancer

NTCP model for hypothyroidism after supraclavicular-directed radiation therapy for breast cancer: Breast cancer is the most common malignancy among women and second most common in the world, with approximately 1.67 million new cases diagnosed and half a million deaths worldwide in 2012 [1]. The standard treatment regimen for breast cancer varies based on stage and clinical presentation, but typically involves surgery, radiation therapy (RT), and systemic therapy. For patients at high-risk for locoregional recurrence, including those with axillary lymph node involvement, RT involving the breast (or chest wall in the case of post-mastectomy RT) and regional lymph nodes has been demonstrated to decrease the local recurrence risk and improve long-term survival [2,3].